Mounjaro Ireland Quick Online Prescription for €20
A secure online assessment — consultation from €20
Why us?
Ireland’s #1 online healthcare platform
As more Irish patients begin treatment with GLP-1 medications, clinicians are observing a familiar pattern:
Initial weight loss is often substantial, but a subset of patients plateau despite excellent adherence, lifestyle changes, and full escalation to the currently approved maximum dose of Wegovy.
This unmet clinical need has driven the development of Wegovy 7.2 mg, a higher-dose formulation of semaglutide designed to extend weight loss in patients who require greater appetite suppression and metabolic support.
However, it is essential to be clear from the outset:
A secure online assessment — consultation from €20
This article explains what Wegovy 7.2 mg is, why it is being developed, what the science shows, where it is currently approved, when it may become available in Ireland, and how Irish patients can safely and legally access weight loss injections today through smartscript.ie.
Wegovy is the brand name for semaglutide, a medication developed by Novo Nordisk and specifically approved for chronic weight management.
Semaglutide belongs to a class of medicines known as GLP-1 receptor agonists. GLP-1 (glucagon-like peptide-1) is a naturally occurring gut hormone that plays a central role in:
In people with obesity, these signalling pathways often function abnormally, driving persistent hunger, cravings, and weight regain. Semaglutide works by restoring and amplifying these signals, allowing patients to eat less without constant hunger or deprivation.
As of 2026, Wegovy is approved in Ireland up to a maximum maintenance dose of 2.4 mg once weekly.
The standard titration schedule typically involves:
For many patients, this regimen produces clinically meaningful weight loss of 10–15% or more, alongside improvements in blood pressure, cholesterol, insulin resistance, and overall quality of life.
However, obesity is a heterogeneous condition, and not all patients respond identically.
Clinical trials and real-world data have demonstrated that while standard Wegovy is highly effective, some patients experience a plateau after initial success. This plateau is not necessarily due to poor adherence or lifestyle factors, but rather reflects:
To address this, researchers explored whether higher doses of semaglutide could deliver additional benefit in patients who tolerate lower doses well but require greater pharmacological support.
The result is Wegovy 7.2 mg.
Wegovy 7.2 mg is a higher-dose semaglutide regimen designed for advanced weight management. It delivers three times the weekly dose of standard Wegovy maintenance.
Key points:
Importantly, Wegovy 7.2 mg is not simply “stronger Wegovy for everyone”. It is a targeted escalation for patients with defined clinical need.
The mechanism of action is the same as standard semaglutide, but the magnitude and duration of effect are greater.
Central Appetite Control
At higher doses, semaglutide exerts a stronger effect on appetite centres in the brain, particularly within the hypothalamus. Patients often report:
This effect is sometimes described as a reduction in “food noise”.
Gastric Emptying and Satiety
Wegovy slows the rate at which food leaves the stomach. At higher doses, this effect is more pronounced, prolonging satiety and reducing meal frequency.
Hormonal and Metabolic Effects
While Wegovy is licensed for weight management rather than diabetes, semaglutide also:
These effects contribute to sustained fat loss rather than short-term water or muscle loss.
Advanced clinical trials investigating higher-dose semaglutide have demonstrated greater average weight loss compared to standard dosing, with some studies reporting mean reductions exceeding 20% of total body weight over extended treatment periods.
Key observations include:
Side effects were generally consistent with lower doses, though more frequent, reinforcing the need for careful patient selection.
A secure online assessment — consultation from €20
The Current Regulatory Reality
As of early 2026:
The higher-dose formulation has been reviewed by the European Medicines Agency, whose scientific committee has issued a positive opinion.
However, final approval requires a decision by the European Commission, after which the authorisation applies across all EU member states, including Ireland.
This final step is anticipated later in 2026, subject to regulatory timelines.
What This Means for Irish Patients
For patients in Ireland:
At smartscripts.ie, all prescribing follows Irish and EU law. We do not initiate or supply medications that are not authorised for use in Ireland.
Who Might Be Considered for Wegovy 7.2 mg Once Approved?
If and when approval is granted, Wegovy 7.2 mg would likely be considered for:
Side Effects of Wegovy 7.2 mg
Side effects with semaglutide are dose-dependent.
Common Effect
Less Common Effect
Important Contraindications
This reinforces why higher-dose treatment must be supervised closely.
Is Wegovy 7.2 mg Safe?
Clinical data suggests that, in appropriately selected patients, higher-dose semaglutide has a safety profile broadly consistent with standard dosing, though side effects may be more frequent.
Safety depends on:
What Can Irish Patients Access Right Now?
While Wegovy 7.2 mg awaits approval, Irish patients can legally access:
All treatment must be:
smartscripts.ie’s Approach to Weight Loss Injections
SmartScripts.ie provides regulated, evidence-based weight management for adults in Ireland.
Our model includes:
We prioritise patient safety and regulatory integrity, particularly as new treatments emerge.
Preparing for Future Treatments Like Wegovy 7.2 m
Patients interested in higher-dose options in the future can prepare by:
This ensures readiness if advanced options become available.
A secure online assessment — consultation from €20
Safety, Monitoring, and Ongoing Review
Answer a few quick questions. An Irish GP reviews your request. Once approved, your prescription is issued directly to your pharmacy.
Disclaimer: All prescriptions are issued by Irish-registered doctors, subject to clinical suitability. Medication names mentioned are trademarks of their respective owners.
Disclaimer: All medicine names and trademarks are the property of their respective owners. SmartScripts does not claim any affiliation with or endorsement by the trademark holders.